Target Research Articles

  1. The Matchmaker Modality: Engineering Event-Driven Pharmacology With Induced Proximity 2/24/2026

    Induced proximity has evolved into a versatile platform with the potential to change drug discovery, but challenges still remain.

  2. A State Of Stress: Developing Therapeutics Rooted In Cell Behavior 2/24/2026

    We caught up with Yerem Yeghiazarians, CEO of Soley Therapeutics, to discuss how capturing the complexity of disease requires going beyond a single target.

  3. Beyond KRAS G12C: New Approaches For Drugging The Undruggable 2/20/2026

    RAS was considered among the holy grail of oncology targets, but over the past decade, this has started to change. A second wave is making its way through R&D to address current shortcomings.

  4. Building Inclusivity Into Early-Stage Preclinical Drug Discovery 2/13/2026

    Systematically reporting both ancestry and sex as standard biological variables may foster more representative and translationally relevant approaches to drug discovery.

  5. Annual Reflections And Predictions From The Editors' Roundtable 1/6/2026

    Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.

  6. Hibernating Squirrels May Hold Clues To Treating Heart Failure 1/2/2026

    Examining natural mechanisms of cardiac repair in hibernating squirrels has provided insight into biological pathways that could help develop a therapeutic for HFpEF.

  7. The Unlikely Weapon Against Fentanyl: Your Immune System 12/23/2025

    ARMR Sciences Inc. has developed a vaccine designed with a novel adjuvant, dmLT, to neutralize fentanyl in the bloodstream before it reaches the central nervous system and binds to μ-opioid receptors (MORs). 

  8. 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026 12/15/2025

    Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.

  9. Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs 11/13/2025

    According to a recent poll, 45% of participants believe the NAMs industry should expand pre-competitive consortia by sharing validation data and best practices to reduce duplication and accelerate acceptance. Experts Zahar Nahle, Ph.D. and Samantha Atkins, Ph.D. share their insights.

  10. The Rise Of NAMs 7/31/2025

    New Approach Methods (NAMs) are rapidly being accepted as replacements for preclinical animal tests long considered to be the gold standard. NAMs include systems of organoids, organs-on-chips, AI-based prediction models, and non-mammalian species.